Price T Rowe Associates Inc. MD Acquires 89,579 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• Price T Rowe Associates Inc. MD increased its stake in Regeneron Pharmaceuticals by 4.3%, acquiring an additional 89,579 shares to hold about 1.99% of the company, valued at approximately $1.38 billion.
• Regeneron reported $12.89 earnings per share (EPS) for the last quarter, significantly exceeding analysts' expectations of $8.43, along with a year-over-year revenue growth of 3.6%.
• The company announced a quarterly dividend of $0.88 per share, providing an annual yield of 0.6% and showcasing a low payout ratio of 8.87%.

Price T Rowe Associates Inc. MD boosted its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 4.3% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,175,026 shares of the biopharmaceutical company's stock after purchasing an additional 89,579 shares during the period. Price T Rowe Associates Inc. MD owned about 1.99% of Regeneron Pharmaceuticals worth $1,379,467,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of the business. Pinney & Scofield Inc. purchased a new position in shares of Regeneron Pharmaceuticals during the fourth quarter valued at approximately $25,000. E Fund Management Hong Kong Co. Ltd. lifted its stake in Regeneron Pharmaceuticals by 344.4% in the first quarter. E Fund Management Hong Kong Co. Ltd. now owns 40 shares of the biopharmaceutical company's stock worth $25,000 after acquiring an additional 31 shares during the period. Costello Asset Management INC bought a new stake in Regeneron Pharmaceuticals in the first quarter valued at $27,000. Tompkins Financial Corp bought a new stake in Regeneron Pharmaceuticals in the first quarter valued at $32,000. Finally, Curat Global LLC purchased a new position in Regeneron Pharmaceuticals during the 1st quarter valued at $32,000. Hedge funds and other institutional investors own 83.31% of the company's stock.

Regeneron Pharmaceuticals Price Performance

Shares of REGN opened at $598.16 on Friday. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $476.49 and a fifty-two week high of $1,211.20. The firm's 50-day simple moving average is $549.27 and its two-hundred day simple moving average is $592.95. The stock has a market cap of $63.40 billion, a PE ratio of 15.07, a price-to-earnings-growth ratio of 1.97 and a beta of 0.33. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.72 and a current ratio of 4.60.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share (EPS) for the quarter, beating the consensus estimate of $8.43 by $4.46. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. The firm had revenue of $3,675,600 billion during the quarter, compared to analyst estimates of $3.30 billion. During the same period last year, the business earned $11.56 earnings per share. The business's revenue was up 3.6% on a year-over-year basis. Analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 3rd. Shareholders of record on Monday, August 18th will be paid a dividend of $0.88 per share. The ex-dividend date is Monday, August 18th. This represents a $3.52 dividend on an annualized basis and a yield of 0.6%. Regeneron Pharmaceuticals's payout ratio is presently 8.87%.

Wall Street Analyst Weigh In

Several research firms have recently commented on REGN. Wells Fargo & Company cut shares of Regeneron Pharmaceuticals from an "overweight" rating to an "equal weight" rating and set a $580.00 target price for the company. in a research report on Friday, August 1st. Citigroup reissued a "buy" rating and issued a $650.00 price target on shares of Regeneron Pharmaceuticals in a research note on Friday, August 1st. Wall Street Zen lowered shares of Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Thursday, May 1st. Guggenheim upped their target price on Regeneron Pharmaceuticals from $810.00 to $815.00 and gave the stock a "buy" rating in a report on Friday, August 1st. Finally, Robert W. Baird decreased their target price on Regeneron Pharmaceuticals from $759.00 to $652.00 and set a "neutral" rating for the company in a research report on Friday, April 25th. Three investment analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating, six have issued a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $829.65.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.